share_log

Benchmark Reiterates Speculative Buy on Biolase, Maintains $0.4 Price Target

Benzinga ·  May 14 11:43

Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment